References
- Food and Drug Administration Amendments Act of 2007. http://www.fda.gov/oc/initiatives/HR3580.pdf (Accessed January 26, 2008)
- Groves T. Mandatory disclosure of trial results for drugs and devices. New US law will require public posting of all the main results and data on harms. BMJ 2008. 336:170
- Grassley, Charles. Testimony before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce. House of Representatives, 110th Congress. The Adequacy of FDA to Assure the Nation's Drug Supply February 13 2007. 17. http://frwebgate.access.gpo.gov/cgi-bin/useftp.cgi?IPaddress=162.140.64.184&filename=35502.wais&directory=/diska/wais/data/110_house_hearings (Accessed February 22, 2008)
- Rennie D. Thyroid storm. JAMA 1997; 277: 1238–43
- Davidoff F, DeAngelis CD, Drazen JM, . Sponsorship, authorship, and accountability. JAMA 2001; 286: 1232–4
- Turner EH, Matthews AM, Linardatos E, . Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252–60
- Rubenstein S, Johnson A. Study missteps threaten turnaround at Schering. Wall Street JournalJanuary 172008. B1
- Evaluation FDA Center for Drug and Research. Early communication about an ongoing data review for ezetimibe/simvastatin (marketed as Vytorin), ezetimibe (marketed as Zetia), and simvastatin (marketed as Zocor). http://www.fda.gov/cder/drug/early_comm/ezetimibe_simvastatin.htm (January 25, 2008)
- Drazen J, Morrissey S, Curfman GD. Open clinical trials. N Engl J Med 2007; 357: 1756–7
- De Angelis CD, Drazen JM, Frizelle FA, . Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. N Engl J Med 2005; 352: 2436–8
- Laine C, Horton R, De Angelis CD, . Clinical trial registration: looking back and moving ahead. BMJ 2007; 334: 1177–8
- Zarin D, Tse T. Moving toward transparency of clinical trials. Science 2008; 319: 1340–42
- Juurlink DN, Mamdani MM, Lee DS, . Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study (RALES). N Engl J Med 2004; 351: 543–51
- McMurray JJV, O'Meara E. Perspective. Treatment of heart failure with spironolactone – trial and tribulations. N Engl J Med 2004; 351: 526–8
- Rockhold FW, Krall RL. Trial summaries on results databases and journal publication. The Lancet 2006; 367: 1635–6
- Nissen S, Wolski K. Effect of rosiglitazone on the risk of myocardial infarct-tion and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–61
- Diamond G, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Int Med 2007; 147: 578–81
- Mulrow CD, Cornell JE, Localio AR. Editorial. Rosiglitazone: A thunderstorm from scarce and fragile data. Ann Int Med 2007; 147: 585–7
- Rockhold F, Snapinn S. Improving the image of pharmaceutical industry research: Transparency is not always clear. Biopharm Report 2007; 15: 2–12